A Study of LY3549492 in Healthy Participants
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called LY3549492 to see if it is safe and tolerable for healthy people. Researchers will take blood samples to find out how much of the drug gets into the bloodstream and how the body handles it. The study will last for a few months for each participant.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study is for healthy participants, it's possible that taking certain medications might affect eligibility. It's best to discuss your specific medications with the trial coordinators.
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Participants receive LY3549492 as single ascending doses
Treatment Part B
Participants receive LY3549492 as multiple ascending doses
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LY3549492
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University